TWI848171B - 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物 - Google Patents

含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物 Download PDF

Info

Publication number
TWI848171B
TWI848171B TW109128895A TW109128895A TWI848171B TW I848171 B TWI848171 B TW I848171B TW 109128895 A TW109128895 A TW 109128895A TW 109128895 A TW109128895 A TW 109128895A TW I848171 B TWI848171 B TW I848171B
Authority
TW
Taiwan
Prior art keywords
ophthalmic composition
aqueous ophthalmic
eye
day
sodium
Prior art date
Application number
TW109128895A
Other languages
English (en)
Chinese (zh)
Other versions
TW202122094A (zh
Inventor
森島健司
浅田博之
桃川雄介
神村明日香
遠藤健一
Original Assignee
日商參天製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商參天製藥股份有限公司 filed Critical 日商參天製藥股份有限公司
Publication of TW202122094A publication Critical patent/TW202122094A/zh
Application granted granted Critical
Publication of TWI848171B publication Critical patent/TWI848171B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109128895A 2019-08-27 2020-08-25 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物 TWI848171B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019154525 2019-08-27
JP2019-154525 2019-08-27

Publications (2)

Publication Number Publication Date
TW202122094A TW202122094A (zh) 2021-06-16
TWI848171B true TWI848171B (zh) 2024-07-11

Family

ID=74685901

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109128895A TWI848171B (zh) 2019-08-27 2020-08-25 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物

Country Status (7)

Country Link
JP (3) JP6966667B2 (enExample)
KR (2) KR102656181B1 (enExample)
CN (2) CN114286670B (enExample)
MY (1) MY209059A (enExample)
PH (1) PH12022550474A1 (enExample)
TW (1) TWI848171B (enExample)
WO (1) WO2021039748A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
JP7175431B1 (ja) 2021-03-30 2022-11-18 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有懸濁液
CN114646705A (zh) * 2022-03-22 2022-06-21 武汉绿合医药科技有限公司 一种地夸磷索钠滴眼液有关物质含量检测方法
JP2024043685A (ja) * 2022-09-20 2024-04-02 参天製薬株式会社 ジクアホソルまたはその塩を含有する眼科用組成物のｐＨの低下を抑制する方法
JP7245383B1 (ja) 2022-09-20 2023-03-23 参天製薬株式会社 ジクアホソルまたはその塩を含有する眼科用組成物のｐＨの低下を抑制する方法
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090994A1 (ja) * 2010-12-28 2012-07-05 参天製薬株式会社 ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0365270A (ja) 1989-07-31 1991-03-20 Kanzaki Paper Mfg Co Ltd 塗布シートの製造方法
JPH0365270U (enExample) 1989-10-31 1991-06-25
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
KR100549904B1 (ko) * 1996-03-27 2006-05-16 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 우리딘트리포스페이트및관련화합물을함유하는섬모운동장해치료용약학조성물
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
WO2001047532A1 (en) * 1999-12-27 2001-07-05 Santen Pharmaceutical Co., Ltd. System for stabilizing lacrimal fluid layer
AU2001260643B9 (en) * 2000-05-30 2006-10-19 Merck Sharp & Dohme Corp. Ectocornea extension promoters
KR101389300B1 (ko) * 2005-02-14 2014-04-25 존슨 앤드 존슨 비젼 케어, 인코포레이티드 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈
CA2810481C (en) * 2010-09-10 2018-06-19 Santen Pharmaceutical Co., Ltd. Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
KR20120077080A (ko) 2010-12-30 2012-07-10 동우 화인켐 주식회사 광학필름 및 이를 이용한 백라이트 유닛
US20160213708A1 (en) * 2012-01-08 2016-07-28 Medicure Technologies Ltd. Ophthalmic composition
MY169816A (en) * 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
JP2015032653A (ja) 2013-08-01 2015-02-16 株式会社東芝 固体撮像装置
JP6267003B2 (ja) 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
EP3139903B1 (en) * 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
EA034517B1 (ru) * 2014-12-25 2020-02-17 Сантен Фармасьютикал Ко., Лтд. Водный офтальмологический раствор
WO2016195072A1 (ja) * 2015-06-05 2016-12-08 参天製薬株式会社 ソフトコンタクトレンズが装用されたドライアイ患者の眼に点眼されるように用いられることを特徴とするドライアイ治療剤
CN107837276A (zh) * 2016-09-19 2018-03-27 刘力 局部给药的药物组合物
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090994A1 (ja) * 2010-12-28 2012-07-05 参天製薬株式会社 ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法

Also Published As

Publication number Publication date
WO2021039748A1 (ja) 2021-03-04
KR20220052971A (ko) 2022-04-28
MY209059A (en) 2025-06-18
JP2025031918A (ja) 2025-03-07
JPWO2021039748A1 (ja) 2021-09-30
JP2022003099A (ja) 2022-01-11
CN117771172A (zh) 2024-03-29
KR102656181B1 (ko) 2024-04-08
PH12022550474A1 (en) 2023-03-06
JP7902251B2 (ja) 2026-08-07
JP6966667B2 (ja) 2021-11-17
TW202122094A (zh) 2021-06-16
CN114286670A (zh) 2022-04-05
JP7614069B2 (ja) 2025-01-15
KR20240049646A (ko) 2024-04-16
CN114286670B (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
JP7614069B2 (ja) ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
JP7796782B2 (ja) ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物
JP7824362B2 (ja) ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
HK40065412B (en) Diquafosol or salt thereof, and aqueous ophthalmic composition containing polyvinylpyrrolidone
HK40037570B (en) Ophthalmic composition comprising diquafosol and cationic polymer
HK40065412A (en) Diquafosol or salt thereof, and aqueous ophthalmic composition containing polyvinylpyrrolidone
HK40037570A (en) Ophthalmic composition comprising diquafosol and cationic polymer